Petros Pharmaceuticals, Inc. (PTPI)

NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals LLC ("Metuchen"), including its wholly owned subsidiaries, Timm Medical Technologies, Inc. and Pos-T-Vac, LLC, from its consolidated balance sheet, effective beginning in its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025. This move is expected to significantly improve Petros' financial position, increasing stockholders' equity and materially reducing consolidated debt.

The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros' securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker "PTPI".

With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces its partnership with Innolitics, a leading developer in the Software-as-a-Medical Device space.

Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces it has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. The AI Platform is expected to be a key component of the Company's recently announced SaaS-based technology, integrating Petros' Software as a Medical Device ("SaMD") proprietary solution, which is being designed to help facilitate expanding access for established prescription drugs by bringing them over the counter.

Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (MAHA) initiative NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a concerted effort toward evolving into a smart healthcare technology company through the development of a SaaS platform designed to complement its proprietary web application (also known as a Software as a Medical Device, or SaMD). The licensable platform is being designed to integrate key cloud-based components, including AI, electronic health records, cybersecurity and others to provide potential prescription treatments and pharmaceutical sponsors with a commercially viable and enterprise scaled platform.

Company's AI and Big Data technology positioned to drive strong industry collaboration Company also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today highlights President Trump's April 15, 2025 Executive Order, titled, "Lowering Drug Prices By Once Again Putting Americans First" (the "Executive Order"), as a demonstration that the Company's recent strategic shift is well timed to the current regulatory climate, where Petros believes it has already made significant advancements. Petros' development of its Big Data and AI-driven software-as-a-Medical Device platform presents an important opportunity for the pharmaceutical industry to contribute to the lowering of drug prices while utilizing an emerging, yet proven, methodology that conforms with FDA guidance to ensure a safe transition from Rx to OTC.

Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces a collaboration with renowned Big Data and analytics leader to enhance the development of its proprietary technology solutions designed to facilitate Rx-to-OTC switches for pharmaceutical products. The collaboration will incorporate an automated credentialing solution to help improve the Company's identity verification system, which also encompasses an AI component.

Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces top-line results of its expanded Application Comprehension ("App Comp") study, which determines consumer comprehension of its unique messaging within its proprietary Technology. In the study, the Company's technology facilitated consumer's understanding of designated critical objectives (with a success threshold of 90% or 85% based on clinical significance of the objective).

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces the pricing of a public offering of approximately 40,000,000 shares of the Company's common stock ("Common Stock"), par value $0.0001 per share (or pre-funded warrants in lieu thereof), with each share of Common Stock (or pre-funded warrant) accompanied by (i) a Series A Warrant to purchase 0.25 share of Common Stock at an exercise price of $0.48 per 0.25 share ("Series A Warrant") and (ii) a Series B Warrant to purchase one (1) share of Common Stock at an exercise price of $0.48 per share ("Series B Warrant"). The combined public offering price of each share of Common Stock together with the accompanying Series A Warrant and Series B Warrant is $0.24, and the combined public offering price of each pre-funded warrant together with the accompanying Series A Warrant and Series B Warrant is $0.2399, which represents the per share offering price for the Common Stock less the $0.0001 per share exercise price for each pre-funded warrant.

Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") by the United States Food and Drug Administration (the "FDA") for companies seeking Rx-to-OTC switch for pharmaceutical products. The Company's recently announced shift in its primary business strategy was initially developed under guidance of earlier iterations of the rule, and the Company believes the final rule will help facilitate the development of its Software as a Medical Device (SaMD) concept, which is designed to serve the emerging self-care market.

Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announced that in a recent podcast, The Intelligent Leadership Podcast, titled, "The New Era of Healthcare, AI, Data and Consumer Empowerment," Petros President Fady Boctor discussed the Company's concerted efforts to develop its proprietary platform as a prospective technology driven Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. During the podcast, Boctor discussed Petros' technology tool development around a Drug Facts Label to self-select, as well as the utilization of AI to ensure safe engagement and access to a drug that has made the Rx-to-OTC switch.

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. If this Software as a Service ("SaaS") and Software as a Medical Device (SaMD) concept is ultimately approved by the FDA, it could significantly serve the emerging self-care market currently estimated to be valued over $38 billion with an expected compounded annual growth rate of 5.6% over the next 10 years.

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored > 80% comprehension PE.

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference.

Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of a subsequent analysis of its pivotal study aimed at facilitating FDA-approved OTC access of the Company's STENDRA® (avanafil) for consumers. This analysis suggested support for the primary study results and demonstrated improved correct self-selection outcomes resulting from patients using the Company's proprietary Web App Technology and its embedded clinically validated diagnostic tool relative to subsequent verbal interviews that were designed into the study protocol as a form of validation of an ED diagnosis.

Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating FDA-approved OTC access of STENDRA® (avanafil) for consumers. The pivotal self-selection study showed that consumers who used the Company's proprietary Web App Technology, designed to assist in the appropriate consumer self-selection for receiving the drug, had a statistically significant (p